Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)

Tipranks - Tipranks - Wed Apr 15, 11:02AM CDT

In a report released yesterday, Graham Parry from Citi maintained a Buy rating on Novartis AG. The company’s shares closed today at CHF120.62.

Claim 30% Off TipRanks

According to TipRanks, Parry is a 2-star analyst with an average return of 0.9% and a 60.00% success rate. Parry covers the Healthcare sector, focusing on stocks such as Roche Holding AG, AstraZeneca, and GlaxoSmithKline.

In addition to Citi, Novartis AG also received a Buy from Kepler Capital ‘s David Evans in a report issued on April 2. However, on April 10, UBS maintained a Hold rating on Novartis AG (Six Swiss: NOVN).

See today’s best-performing stocks on TipRanks >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).